Which biomarker antigens & antibodies are needed for viral hepatitis panels? Key Raw Material Guide

The specific biomarker antigens and antibodies needed to build a differential immunoassay panel for viral hepatitis screening center on a core set of serological markers that distinguish acute Hepatitis A, acute/chronic Hepatitis B, and Hepatitis C exposure. You require IgM anti-HAV, HBsAg, IgM anti-HBcAg, and anti-HCV as the non-negotiable initial targets. To develop ELISA or CLIA kits for these markers, you must source high-purity recombinant antigens (like HAV antigen, HBcAg, and HCV chimeric antigens) and high-affinity monoclonal antibodies—particularly anti-HBsAg capture–detection pairs—to achieve unambiguous differentiation without cross-reactivity.

The essential viral hepatitis differential panel combines host antibody detection (IgM anti-HAV, IgM anti-HBcAg, anti-HCV) with direct antigen detection (HBsAg). Making it reliable demands rigorously validated monoclonal antibodies and high-quality recombinant antigens to eliminate false positives and distinguish acute from chronic disease in a single workflow.

The Core Differential Panel: Antigen and Antibody Targets

Every differential panel must simultaneously answer three questions: Is this acute Hepatitis A? Is there an active Hepatitis B infection? Has this patient been exposed to Hepatitis C? The four markers below answer those questions, and each demands specific reagent formats.

Hepatitis A Virus (HAV): Capturing the Acute Marker

Acute HAV diagnosis relies on a single host antibody: IgM anti-HAV. It appears with symptom onset and persists for 3–6 months, giving the definitive serological footprint of current infection.

To build this assay, kit manufacturers need high-purity HAV recombinant antigen to capture patient IgM. The same antigen can also be used in total antibody (IgG) tests for immunity screening, but the acute differentiation hinges on an IgM-capture format—meaning the solid phase is coated with anti-human IgM, and the signal is generated by labeled HAV antigen.

Hepatitis B Virus (HBV): The Surface Antigen and Core Antibody Duo

HBV requires simultaneous detection of a viral protein and a host immunoglobulin to pinpoint infection stage:

• HBsAg (Hepatitis B surface antigen) is the universal marker of active HBV infection, whether acute or chronic.
• IgM anti-HBcAg (IgM antibody to core antigen) confirms that the infection is acute or a severe flare of chronic disease.

The raw material backbone for these assays is critical. You need anti-HBsAg monoclonal antibody pairs—one for capture, one for detection—to build a highly sensitive HBsAg sandwich assay. For anti-HBc detection, high-purity recombinant HBcAg is essential. These reagents must eliminate cross-reactivity between anti-HBc IgM and IgG to allow clear staging.

Staging Chronic HBV: Additional Markers for Deep Profiling

Once HBsAg positivity is established, a full chronic HBV staging panel adds:

• HBeAg and anti-HBe to categorize viral replication activity.
• Total anti-HBc (IgG-dominant) to confirm past or ongoing infection.
• Anti-HBs to identify resolved infection or vaccine-induced immunity.

For IVD developers, this means sourcing recombinant HBeAg and HBcAg of sufficient purity to distinguish subtle serological patterns, especially in HBeAg-negative chronic hepatitis or occult HBV, where HBsAg may be absent and anti-HBc becomes the sole footprint.

Hepatitis C Virus (HCV): Screening for Exposure

Anti-HCV screening is the entry point. Assays use chimeric recombinant antigens that incorporate immunodominant epitopes from the core, NS3, NS4, and NS5 proteins to maximize sensitivity. Confirmatory testing often adds an HCV core antigen detection module, which requires its own specific monoclonal antibody pairs to recognize circulating viral protein even before seroconversion.

Hepatitis D and E (HDV/HEV): Extended Differential Targets

When epidemologically or clinically indicated, adding anti-HDV IgM/IgG and anti-HEV IgM/IgG completes the differential. These are built with respective recombinant antigens—HDV antigen (the delta protein) and HEV capsid antigen—again demanding high specificity to avoid false-positive signals in co-infection scenarios.

Raw Material Requirements for High-Performance Assays

The performance of any panel lives or dies on the quality of its key immunoreagents. Three material categories define analytical sensitivity and specificity.

Monoclonal Antibodies for Antigen Capture

The most demanding target is HBsAg, which must be detected across genotypes and subtypes at sub‑ng/mL concentrations. Developers need carefully selected anti-HBsAg monoclonal antibody pairs that bind non-overlapping epitopes, tolerate serum matrix effects, and show zero cross-reactivity with other hepatitis antigens. Similar logic applies to HCV core antigen pairs if building an antigen-only screening approach.

Recombinant Antigens for Antibody Detection

Each serological arm requires a defined recombinant antigen:

• HAV antigen (often VP1/VP3 capsid protein constructs) for anti-HAV IgM and total antibody assays.
• HBcAg for anti-HBc IgM and total IgG detection.
• HBeAg for anti-HBe tests.
• HCV chimeric antigens (core+NS3+NS4+NS5 fusions) for anti-HCV screening.
• Optional HDV delta antigen and HEV ORF2 protein for extended panels.

These proteins must be free of bacterial contaminants, correctly folded, and manufactured under consistent protocols to ensure lot-to-lot reproducibility in diagnostic kits.

Reference Standards and Calibrators

Reliable differential panels are anchored to international reference preparations. Incorporating WHO standards or calibrated in-house panels tied to those standards allows you to set cutoffs that distinguish acute infection from past exposure and to categorize chronic HBV phases with clinical confidence.

Navigating Trade-offs and Pitfalls

Building a hepatitis differential panel is as much about managing interference as it is about selecting targets. The wrong raw material choice can create costly false pathways.

Cross-Reactivity Destroys Staging Accuracy

The most dangerous pitfall is serological cross-reactivity between viral markers. For example, a weakly specific anti-HBc IgM assay can produce false acute signals in chronic HBeAg-negative hepatitis, leading to misclassification. Using highly specific monoclonal antibodies and pure recombinant antigens mitigates this risk but often requires extensive epitope-mapping and screening against heterologous sera.

Sensitivity Gaps in Occult HBV and Early HCV

Occult HBV (HBsAg-negative, anti-HBc-positive with low HBV DNA) demands anti-HBc total assays with high analytical sensitivity to avoid missing latent cases. Similarly, anti-HCV alone misses the window period before seroconversion. Including an HCV core antigen detection module closes this gap but adds complexity and cost.

The Simplicity–Completeness Trade-off

A basic four-marker panel (IgM anti-HAV, HBsAg, IgM anti-HBc, anti-HCV) handles acute differentials efficiently but says little about chronic HBV phase or protective immunity. Adding HBeAg, anti-HBe, anti-HBs, and total anti-HBc enriches clinical utility but increases panel cost, multiplexing complexity, and regulatory burden. Every developer must balance diagnostic coverage against operational feasibility.

Sample Volume and Throughput

Each added analyte consumes sample volume and instrument time. In high-throughput settings, consolidating the core markers into a single multi-analyte CLIA cassette with careful channel allocation can preserve speed without sacrificing differential power.

Making the Right Choice for Your Diagnostic Panel

Select the combination of antigen and antibody targets based on the clinical scenario your kit is designed to serve.

• If your primary focus is acute hepatitis screening: Build on the four-core quartet: IgM anti-HAV (using HAV antigen), HBsAg (using anti-HBs mAb pairs), IgM anti-HBc (using HBcAg), and anti-HCV (using chimeric antigens). This covers the urgent differential without excess cost.
• If your primary focus is chronic HBV staging: Expand the panel with HBsAg, total anti-HBc, IgM anti-HBc, HBeAg, anti-HBe, and anti-HBs—all supported by high-purity recombinant HBsAg, HBcAg, and HBeAg, plus validated monoclonal antibody pairs for each antigen detection.
• If your primary focus is vaccination response verification: A total anti-HAV and anti-HBs quantitative assay using HAV antigen and HBsAg, respectively, provides the necessary immunity fingerprint.
• If your primary focus is a comprehensive, all-in-one differential: Integrate HAV, HBV (full staging set), HCV (anti-HCV plus optionally HCV core Ag), and HDV/HEV markers, with rigorous reagent quality control to avoid cross-reactivity across this broad analyte spectrum.

Empower your panel design with the right raw materials—specific monoclonal antibodies and pure recombinant antigens—and you turn a simple immunoassay array into a definitive tool for distinguishing viral hepatitis at the first blood draw.

Summary Table:

Accelerate Your Hepatitis Diagnostic Panel Development with CamelBio

Developing high-performance differential immunoassay panels requires rigorously validated, high-affinity raw materials to eliminate cross-reactivity and ensure clear clinical staging.

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. Whether you need premium anti-HBsAg monoclonal antibody pairs, pure recombinant HBcAg/HBeAg, or custom chimeric HCV antigens, our diagnostic experts are here to power your assay performance.

Contact us today to request reagent samples or discuss your panel development needs!